News | April 25, 2023
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
The survey inspected ambulances operating throughout the city
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Integration of modern and traditional medicine to facilitate the illness to wellness journey
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
These patches can be used in settings where patients need close vital signs monitoring, including cardiac rhythm.
Subscribe To Our Newsletter & Stay Updated
